Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryCan the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthmaLung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cellsInvolvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitorThe effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activationChemical ecology: a view from the pharmaceutical industryDrug treatment of airway inflammation in asthma.Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C).Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigsThe effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis.Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors.Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchusEffects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbitsThe inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisyIdentification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregationPossible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle toneEffects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pigAntiinflammatory therapies for cystic fibrosis: past, present, and future.Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Value of theophylline treatment in patients handicapped by chronic obstructive lung diseaseE-type prostaglandins enhance local oedema formation and neutrophil accumulation but suppress eosinophil accumulation in guinea-pig skin.Phosphodiesterase inhibitors.Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.Treating COPD with PDE 4 inhibitors.Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.Targeting cancer with phosphodiesterase inhibitors.Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseTherapeutic potential of boron-containing compounds.Substituted oxadiazoles: a patent review (2010 - 2012).Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.
P2860
Q21089854-3DF62F6D-CC41-4891-B864-5A166A1A69DAQ24651941-164F2203-ED7F-489F-8B0A-7033F8AF70AEQ24804029-918E3033-CCE5-43EA-AB66-DCABF2451DB3Q24815216-46727638-C615-4743-926F-D9A976A9C692Q28289122-4314B1AA-CFAA-4E0E-8FBB-8A6ED054A11FQ28354227-C6FADB2B-C3AA-445D-A6BF-3B7260BDBA8DQ28379336-A44B3910-5342-4BF2-8192-0754E88164E6Q30418854-1582EF24-1C39-43E5-91E8-44DA44F92C9FQ34186818-282A4479-2F35-4284-AF24-A815AD42812AQ34317686-3F569E20-CECF-4F2A-BA4F-BA0011C4FAC6Q34458831-4D4E33A8-CC28-4C38-94B8-6E3021680184Q34792244-8054E848-ECBB-4FB5-B45B-F1418B00A2A3Q35041052-EB4E01C6-DD9B-492C-8AAF-79BA6F0E498EQ35041509-968511CB-1347-47F2-A263-94832D2E656BQ35870825-5905E041-A69D-4742-A8DB-74D8229A4CCCQ35871422-46539054-6A75-4DF5-8853-87967D5005E8Q35873464-C0F2D20B-9BD8-4CCF-B7AD-D280051912AEQ35873662-9235B082-4F64-4500-A10B-E851A89B4223Q35873675-75D0F447-CD67-433F-BA1F-B462BFD43435Q35873893-0E1DCBFF-C576-41A0-AD4A-F637E4CCDFD1Q35874125-7509CB70-C539-4217-AE55-0103F6C9ADE6Q35874181-D7BBEB8A-3C23-4A5F-8F0C-F33FBB40D5ECQ35874511-EC298A97-2441-456A-BF60-4BD390BEDBEDQ35874736-3FD30FBA-C95E-47B3-AE42-A1B1606397BEQ36174470-DA291233-B9C3-434C-ACD1-C7245830C420Q36270020-29CF32AE-791B-4DF8-B970-30ECD3A511C9Q36276399-54A9799C-E906-46D0-8B81-78696A950A94Q36330353-40398F33-2F79-499D-A5E0-ED04AA28FDA6Q36364429-89788D6D-1C47-4124-8085-70157E9F57F3Q36886979-3167A015-3953-439A-BD0C-F93603B33B7EQ37082594-4C512C3C-6BDD-449E-A756-6DC2F4394AF1Q37084467-C2E23311-78C6-40E0-BFC8-B803C66849BDQ37139712-7A6A3FE3-8C5A-4A6E-A1E3-FC4ADCF48502Q37650389-7E2FBF68-0F50-40E1-BD8F-77126D50A869Q37732234-13C5426C-62AB-492C-89DF-C9A13A7888B3Q37828179-10DD3830-6791-40E5-8456-FD892D4B3296Q37855884-5D715AE1-4EC5-4E4C-80E0-C699E0F7F53AQ38105642-0B428CDE-CEA7-49B6-811D-7507DB53C6D4Q38296083-432F83AD-2AA2-4A40-8E73-A68521E459C9Q38653998-337F1342-B72D-4140-81F2-9C3CFEF452D1
P2860
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@en
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@nl
type
label
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@en
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@nl
prefLabel
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@en
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@nl
P2860
P356
P1433
P1476
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
@en
P2093
P2860
P304
P356
10.1136/THX.46.7.512
P407
P577
1991-07-01T00:00:00Z